GlassScriptPhysician profile
Scott B Harp
NPI 1831371376
$5,518.27
in general payments reported to CMS, 2019-2025
44 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,083 · 2022: $1,173 · 2023: $1,041 · 2024: $965 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $924.51 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $564.92 | 2021-2025 | |
| Lilly USA, LLC | $559.32 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $303.44 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.50 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $270.23 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $219.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $216.84 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $171.68 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Eisai INC. | $155.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $149.10 | 2022-2025 | |
| Exact Sciences Corporation | $122.54 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $107.29 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $99.64 | 2021-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.42 | 2021-2025 | Xifaxan |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.